Condition

Idiopathic Pulmonary Fibrosis clinical trials and research

• 44Clinical trials
• 30NIH research projects
• 30Countries

Newest Idiopathic Pulmonary Fibrosis clinical trials

All recruiting trials (44)

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Rentosertib by mouth for people with idiopathic pulmonary fibrosis

  This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.

  Recruiting at 12 sites Phase 3 InSilico Medicine Hong Kong Limited · Hefei, Anhui and 46 other locations · NCT07687459

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

• Nalbuphine Extended-Release Tablets to Reduce IPF-Related Chronic Cough

  A Phase 3 trial tests whether nalbuphine extended-release tablets can lessen chronic cough in adults with idiopathic pulmonary fibrosis compared with a placebo.

  Recruiting at 22 sites Phase 3 Trevi Therapeutics · Newport Beach, California and 21 other locations · NCT07671911

• Find a safe, effective dose of CHF10067 (zampilimab) for people with IPF

  This study tests two different doses of CHF10067 against placebo to see if they can help people with idiopathic pulmonary fibrosis.

  Recruiting at 19 sites Phase 2 Chiesi Farmaceutici S.p.A. · Dothan, Alabama and 18 other locations · NCT07516951

• See if ENV-101 interacts with IPF medicines like nintedanib and pirfenidone

  This study tests whether taladegib (ENV-101) changes how IPF drugs work in healthy people to see if there are drug interactions and to describe how the drug moves through the body.

  Recruiting at 2 sites Phase 1 Endeavor Biomedicines, Inc. · Brisbane, Queensland and 1 other locations · NCT07454291

• Safety and how the body handles SRN001 in healthy Korean and Caucasian men

  This will test whether repeated doses of the experimental siRNA drug SRN001 are safe and how the body processes it in healthy Korean and Caucasian adult men.

  Recruiting Phase 1 siRNAgen Therapeutics Inc. · Seoul · NCT07407543

• Small airways function testing in idiopathic pulmonary fibrosis (SWIFT-IPF)

  We will use a breathing test called the nitrogen washout to see if adults with idiopathic pulmonary fibrosis have small airway problems before starting medication.

  Recruiting at 2 sites University of Milan · Milan, Lombardy and 1 other locations · NCT07312305

• IVIG for sudden severe flare-ups of idiopathic pulmonary fibrosis

  This trial will try adding intravenous immunoglobulin (IVIG) to standard hospital care to see if it helps people hospitalized with sudden, severe worsening of idiopathic pulmonary fibrosis.

  Recruiting Phase 3 University General Hospital of Patras · Pátrai · NCT07299695

• PIPE-791 treatment for people with idiopathic pulmonary fibrosis

  This will test two doses of PIPE-791 against placebo to see if they slow lung function decline in adults with idiopathic pulmonary fibrosis, including people already taking approved antifibrotic drugs.

  Recruiting at 109 sites Phase 2 Contineum Therapeutics · Mar del Plata, Buenos Aires and 108 other locations · NCT07284459

• ABBV-142 to check side effects and changes in disease activity in adults with idiopathic pulmonary fibrosis.

  Adults with idiopathic pulmonary fibrosis will be randomly given ABBV-142 or a placebo to see if ABBV-142 is safe and changes disease activity.

  Recruiting at 57 sites Phase 2 AbbVie · Birmingham, Alabama and 56 other locations · NCT07230288

• Daoyin technique to boost exercise endurance in IPF

  A guided Daoyin technique is tested to see if it helps people with idiopathic pulmonary fibrosis exercise longer and more comfortably than standard training.

  Recruiting at 3 sites Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Beijing, Beijing Municipality and 2 other locations · NCT07019714

• Hyperpolarized xenon‑129 MRI for imaging lung function in idiopathic pulmonary fibrosis

  This will test whether inhaling hyperpolarized xenon‑129 during MRI can safely show lung ventilation and perfusion changes over time in people with idiopathic pulmonary fibrosis.

  Recruiting Early Phase 1 University of Virginia · Charlottesville, Virginia · NCT06853145

• Evaluating SB17170 in patients with idiopathic pulmonary fibrosis

  This study is testing a new drug called SB17170 to see if it can help adults with moderate to severe idiopathic pulmonary fibrosis breathe better over 12 weeks.

  Recruiting at 2 sites Phase 2 SPARK Biopharma · Goyang and 4 other locations · NCT06747923

• Senicapoc treatment for worsening fibrotic interstitial lung disease

  This trial will test whether senicapoc can slow or stop worsening lung scarring in adults with progressive fibrotic interstitial lung disease, including idiopathic pulmonary fibrosis.

  Recruiting at 5 sites Phase 2 Vejle Hospital · Aarhus N and 4 other locations · NCT06714123

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Zinc plus nicotinamide riboside for idiopathic pulmonary fibrosis

  This study will test whether taking zinc and nicotinamide riboside twice daily helps people over 50 with idiopathic pulmonary fibrosis and whether participants can complete the study remotely while receiving local care.

  Recruiting Phase 2 Cedars-Sinai Medical Center · Los Angeles, California · NCT06567717

• Beetroot Juice for IPF Patients: A Pilot Test of Nitrate-Rich Supplementation

  This small pilot tests whether nitrate-rich beetroot juice twice daily for 3 days can affect exercise responses in adults with idiopathic pulmonary fibrosis.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton · NCT06488638

• Testing hymecromone in adults with interstitial lung disease

  This study is testing a new medication called hymecromone to see if it can help adults with progressive interstitial lung disease feel better and improve their lung function.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Research Triangle Park, North Carolina · NCT06325696

• Using CT scans and biomarkers to improve treatment for pulmonary fibrosis

  This study is testing if special CT scans and biomarkers can help doctors better understand how severe idiopathic pulmonary fibrosis is and how well treatments are working for patients.

  Recruiting University of Virginia · Charlottesville, Virginia · NCT06323876

• Evaluating the safety and tolerability of SV001 in healthy Chinese adults

  This study is testing a new drug called SV001 in healthy Chinese adults to see if it's safe and how well it works compared to a placebo.

  Recruiting Early Phase 1 Shanghai Synvida Biotechnology Co.,Ltd. · Shanghai · NCT06267183

• Evaluating FAP as a biomarker for fibrotic lung diseases

  This study is testing if a protein called FAP can help doctors understand and track fibrotic lung diseases like idiopathic pulmonary fibrosis by looking at its levels in different samples and using special scans before and after treatments.

  Recruiting Phase 2 Erasme University Hospital · Brussels · NCT06189820

• Evaluating Sufenidone for Idiopathic Pulmonary Fibrosis

  This study is testing a new medication called Sufenidone to see if it can help people with Idiopathic Pulmonary Fibrosis breathe better and stay healthier compared to a placebo.

  Recruiting Phase 2/3 Guangzhou JOYO Pharma Co., Ltd · Beijing, Beijing Municipality · NCT06125327

• Validation of a cough monitoring system

  This study is testing a new wearable device that tracks coughs in patients aged 2 and older to see if it can help doctors better understand and manage respiratory issues.

  Recruiting at 7 sites Cough Monitoring Medical Solutions · Alfena and 7 other locations · NCT05989698

• Artesunate at increasing doses for people with idiopathic pulmonary fibrosis

  This will test whether taking artesunate by mouth at different doses is safe and tolerable for people with idiopathic pulmonary fibrosis.

  Recruiting Phase 1 Stanford University · Stanford, California · NCT05988463

• Azithromycin for acute exacerbations of idiopathic pulmonary fibrosis

  This study will test whether adding azithromycin to standard care helps people with mild to early-moderate acute exacerbations of idiopathic pulmonary fibrosis.

  Recruiting Assiut University · Asyut and 1 other locations · NCT05842681

• Oral Ifetroban for treating Idiopathic Pulmonary Fibrosis

  This study is testing if a new oral medication called ifetroban can help people with Idiopathic Pulmonary Fibrosis feel better and stay safe over a year.

  Recruiting at 18 sites Phase 2 Cumberland Pharmaceuticals · La Mesa, California and 19 other locations · NCT05571059

• Biobank for interstitial lung diseases

  This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas · NCT05392881

• Registry for individuals affected by pulmonary fibrosis

  This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.

  Recruiting Pulmonary Fibrosis Foundation · Chicago, Illinois · NCT05382572

• Guiding PEEP adjustments in patients with pulmonary fibrosis on mechanical ventilation

  This study is testing if adjusting a specific breathing support setting can help patients with pulmonary fibrosis on mechanical ventilation breathe better and improve their health outcomes.

  Recruiting University of Modena and Reggio Emilia · Modena · NCT05098717

• Investigating how lung diseases affect heart function

  This study is trying to see how chronic lung diseases like COPD and asthma affect heart function in patients using special heart imaging techniques.

  Recruiting RWTH Aachen University · Aachen · NCT05042219

• Using Lansoprazole to Treat Idiopathic Pulmonary Fibrosis

  This study is testing if adding Lansoprazole can help people with Idiopathic Pulmonary Fibrosis breathe better and slow down the disease.

  Recruiting at 41 sites Phase 3 Norfolk and Norwich University Hospitals NHS Foundation Trust · Norwich, Norfolk and 56 other locations · NCT04965298

• Observational cohort of patients with worsening idiopathic pulmonary fibrosis

  This study is tracking patients with worsening idiopathic pulmonary fibrosis who need to be hospitalized to see how different biological markers relate to their health and quality of life over time.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup, Copenhagen · NCT04442711

• Using imaging to understand lung inflammation in pulmonary fibrosis

  This study is testing new imaging techniques to see if they can help doctors better understand lung inflammation in people with idiopathic pulmonary fibrosis.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT04362644

• Registry of patients with idiopathic pulmonary fibrosis in South Korea

  This study is collecting information from patients with idiopathic pulmonary fibrosis in South Korea to better understand the disease and improve how it's managed.

  Recruiting Seoul National University Hospital · Seongnam-si · NCT04160715

• Examining muscle function in patients with interstitial lung disease

  This study tests how muscle function affects breathing and exercise in people with interstitial lung disease compared to healthy individuals, and looks at how supplemental oxygen might help.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT03800017

• Lung and bone marrow transplantation for patients with lung and bone marrow failure

  This study tests if doing a lung transplant followed by a bone marrow transplant can help people with severe lung disease and bone marrow failure feel better and live longer.

  Recruiting at 2 sites Phase 1/2 University of Pittsburgh · Pittsburgh, Pennsylvania and 1 other locations · NCT03500731

• Understanding Familial Pulmonary Fibrosis

  This study follows family members of people with a specific lung disease to see how the disease develops over time and what factors might increase their risk of getting pulmonary fibrosis.

  Recruiting Vanderbilt University Medical Center · Nashville, Tennessee · NCT03437486

• Registry of healthy controls for respiratory diseases

  This study is collecting health information from healthy volunteers to help researchers better understand respiratory diseases like asthma and COPD by comparing it to data from patients with these conditions.

  Recruiting Seoul National University Hospital · Seoul, Seoul · NCT03120481

• Observing the natural progression of interstitial lung disease

  This study is collecting data and blood samples from people with interstitial lung disease to see how the condition progresses over time and to better understand its effects.

  Recruiting University of Chicago · Chicago, Illinois · NCT00470327

• Analyzing genetic and biological markers in idiopathic pulmonary fibrosis

  This study is trying to find out if certain genetic and biological markers can help predict how lung function will change over time in people with idiopathic pulmonary fibrosis.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT00373841

NIH-funded research (30)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis

  A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).

  NIH research Oleolive, INC. · Shreveport, United States · NIH-11550918

• Screening new compounds to reverse gene signatures in IPF lungs

  A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).

  NIH research Henry Ford Health + Michigan State University Health Sciences · East Lansing, United States · NIH-11494256

• Unraveling IPF subtypes to guide prognosis and therapy

  This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.

  NIH research University of Kansas Medical Center · Kansas City, United States · NIH-11411171

• Novel antibody therapy to treat idiopathic pulmonary fibrosis

  A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.

  NIH research Vasarya Therapeutics, INC. · Camden, United States · NIH-11382077

• Repurposing Vonoprazan as an inhaled therapy for IPF

  A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).

  NIH research Henry Ford Health + Michigan State University Health Sciences · East Lansing, United States · NIH-11366024

• Proteomic profile of IPF progression to help tailor treatments

  A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11365030

• Adrenergic Nerves and Noradrenaline in Lung Fibrosis

  A physician-scientist-in-training at Yale seeks to build a patient-focused research program on how nerve signals and adrenaline affect lung scarring in IPF.

  NIH research Yale University · New Haven, United States · NIH-11351083

• Improving IPF care for Veterans with a new, practical care model

  A project to help Veterans with idiopathic pulmonary fibrosis get timely, expert, and age-friendly care using a new care model.

  NIH research Durham VA Medical Center · Durham, United States · NIH-11345476

• Bispecific antibody therapy for idiopathic pulmonary fibrosis (IPF)

  A new antibody therapy called VTC-890 is being developed to block two inflammatory signals in IPF to slow lung scarring.

  NIH research Virtici, LLC · Seattle, UNITED STATES · NIH-11320898

• Targeted antibody treatment for idiopathic pulmonary fibrosis

  A new antibody drug designed to stick to and calm scarring in the lungs for people with idiopathic pulmonary fibrosis (IPF).

  NIH research Vasarya Therapeutics, INC. · Camden, United States · NIH-11259230

• Gene therapy to treat idiopathic pulmonary fibrosis by reducing harmful signaling in the lungs

  This study is testing a new gene therapy that uses a virus to help your body break down a harmful substance linked to lung inflammation in people with idiopathic pulmonary fibrosis (IPF), with the hope of improving lung function and managing this tough condition.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11200757

• SGPL1 gene therapy to reduce lung scarring in idiopathic pulmonary fibrosis

  This project uses a one-time viral gene delivery to boost SGPL1 in the lungs and lower sphingosine-1-phosphate to help people with idiopathic pulmonary fibrosis breathe better.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11187012

• Investigating specific FGFR signaling pathways in lung disease

  This study is looking at how certain proteins in the lungs might affect the worsening of Idiopathic Pulmonary Fibrosis (IPF) in older adults, with the hope of finding new treatments to help those living with this condition.

  NIH research Yale University · New Haven, United States · NIH-11117642

• A new treatment for Idiopathic Pulmonary Fibrosis using a bispecific antibody.

  This study is testing a new treatment called VTC-890 that aims to help people with Idiopathic Pulmonary Fibrosis by blocking two proteins that cause lung scarring, with the hope of improving their breathing and overall health.

  NIH research Virtici, LLC · Seattle, UNITED STATES · NIH-11116876

• Understanding how Idiopathic Pulmonary Fibrosis changes over time

  This research aims to find markers in the blood that can help predict how Idiopathic Pulmonary Fibrosis (IPF) will progress in patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11111170

• New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis

  This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.

  NIH research Oncoarendi Therapeutics, LLC · Groton, United States · NIH-11078734

• Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.

  This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.

  NIH research Univ of Massachusetts Med Sch Worcester · Worcester, United States · NIH-11075126

• Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information

  This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11071971

• Identifying biomarkers for rapid progression of idiopathic pulmonary fibrosis

  This study is looking at blood samples from people with rapidly progressing idiopathic pulmonary fibrosis (IPF) to find specific markers that could help doctors detect and treat the disease earlier, making it easier for patients to manage their condition.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11054916

• Investigating new treatments for lung scarring in idiopathic pulmonary fibrosis

  This study is looking for new ways to help people with idiopathic pulmonary fibrosis (IPF) by finding compounds that could change how certain genes work in the lungs, which might lead to better treatments for this tough lung disease.

  NIH research Henry Ford Health + Michigan State University Health Sciences · East Lansing, United States · NIH-11040233

• Investigating the role of the complement pathway in lung diseases

  This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.

  NIH research Duke University · Durham, United States · NIH-11011341

• Investigating how a specific protein affects lung disease development

  This study is looking at how a protein called XBP1S affects another protein, MUC5B, in the lungs of people with idiopathic pulmonary fibrosis (IPF), hoping to find new ways to help treat this serious lung disease.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11001548

• Developing a new treatment for Idiopathic Pulmonary Fibrosis

  This study is testing a new drug called VSR-H5 that aims to help people with Idiopathic Pulmonary Fibrosis (IPF) by targeting only the damaged areas of their lungs, with the hope of improving their health without causing the side effects that come with current treatments.

  NIH research Vasarya Therapeutics, INC. · Camden, United States · NIH-10915918

• Investigating how body fat affects frailty in older patients with lung disease

  This study is looking at how extra body fat might affect weakness in older adults with idiopathic pulmonary fibrosis (IPF), and it hopes to find ways to help improve their health and well-being.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10912580

• Gene therapy to treat idiopathic pulmonary fibrosis by reducing harmful signaling in the lungs

  This study is testing a new gene therapy that aims to help people with idiopathic pulmonary fibrosis (IPF) by using a virus to deliver a gene that can reduce lung inflammation and scarring, which could lead to better lung function and a new treatment option for patients.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10793257

• Creating a 3D model to study lung fibrosis similar to Idiopathic Pulmonary Fibrosis

  This study is creating a special 3D model of Idiopathic Pulmonary Fibrosis (IPF) using stem cells to better understand the disease and find new treatments that could work for different patients.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-10763361

• New treatment targeting IL-17A for idiopathic pulmonary fibrosis

  This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.

  NIH research Targetsite Therapeutics Corporation · New Haven, United States · NIH-10761365

• Using mouse models to improve treatment for idiopathic pulmonary fibrosis

  This study is looking at a serious lung disease called idiopathic pulmonary fibrosis (IPF) in older adults by creating special mouse models to help us learn how certain gene changes affect the disease, with the hope of finding new treatments to help people with IPF feel better.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10754510

• Targeting a specific protein to treat lung fibrosis in ferrets

  This study is looking at how a protein called MUC5B affects idiopathic pulmonary fibrosis (IPF) using ferrets, which have lungs similar to ours, to help find new ways to treat or even reverse the disease.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10745662

• Developing a new treatment for idiopathic pulmonary fibrosis

  This study is looking at a new treatment called M10 that might help people with idiopathic pulmonary fibrosis (IPF) by reducing the harmful changes in their lung cells, with the hope of being more effective and having fewer side effects than current options.

  NIH research Fibrobiologics, LLC · Charleston, United States · NIH-10696538

Related topics

Quick answers

How many Idiopathic Pulmonary Fibrosis clinical trials are recruiting right now?

44, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (18 trials), South Korea (7 trials), United Kingdom (6 trials), China (5 trials), Canada (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 3: 5, Phase 1: 4, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →